您的位置: 首页 » 法律资料网 » 法律法规 »

浙江省实施《农村五保供养工作条例》办法

时间:2024-07-05 17:55:18 来源: 法律资料网 作者:法律资料网 阅读:9794
下载地址: 点击此处下载

浙江省实施《农村五保供养工作条例》办法

浙江省人民政府


浙江省实施《农村五保供养工作条例》办法

省政府令第244号


《浙江省实施〈农村五保供养工作条例〉办法》已经省人民政府第8次常务会议审议通过,现予公布,自2008年8月1日起施行。

省长 吕祖善

二○○八年七月一日

   浙江省实施《农村五保供养工作条例》办法


  第一章 总则

  第一条为规范农村五保供养工作,保障农村五保供养对象的合法权益,根据《农村五保供养工作条例》(以下简称《条例》),结合本省实际,制定本办法。
  第二条本办法所称的农村五保供养,是指依照本办法规定,在吃、穿、住、医、葬等方面给予符合条件的村民提供生活照顾和物质帮助。
  第三条 县级以上人民政府应当加强对农村五保供养工作的领导,将农村五保供养事业纳入国民经济和社会发展规划,统筹安排,协调发展,并加强对农村五保供养工作的监督管理。
  乡(镇)人民政府管理本行政区域内的农村五保供养工作。
  第四条县级以上人民政府民政部门主管本行政区域内的农村五保供养工作。
  县级以上人民政府有关部门,应当按照各自职责做好农村五保供养工作。
  第五条村民委员会应当协助乡(镇)人民政府开展农村五保供养工作。
  第六条鼓励社会组织和个人为农村五保供养对象和农村五保供养工作提供捐助;鼓励国家机关、企事业单位、社会团体及其工作人员开展为农村五保供养对象的志愿者服务。

  第二章 供养对象、内容和形式

  第七条农村五保供养对象应当同时符合下列条件:
  (一)无法定赡养、抚养、扶养义务人,或者虽有法定赡养、抚养、扶养义务人,但是赡养、抚养、扶养义务人无赡养、抚养、扶养能力的;
  (二)无劳动能力的;
  (三)无生活来源的。
  第八条符合农村五保供养对象条件的村民,应当按照《条例》第七条第一款规定向村民委员会提出申请。申请的审核、审批程序按照《条例》第七条第二款的规定执行。
  设区的市、县(市、区)民政部门和乡(镇)人民政府应当将符合条件的村民列入农村五保供养范围,建立农村五保供养对象数据库,做到应保尽保;村民委员会应当根据自治章程明确的职责和村规民约,做好农村五保供养的相关工作。
  农村五保供养对象不再符合供养条件或者死亡的,依照《条例》第八条的规定核销其供养证书。
  第九条农村五保供养的具体内容按照《条例》第九条规定执行。
  农村五保供养对象应当参加新型农村合作医疗,其个人缴费部分由人民政府承担,其医疗费用先按规定在新型农村合作医疗基金中报销,不足部分全额由医疗救助资金解决。
  第十条农村五保供养标准应当按照不低于所在县(市、区)上年度农民人均纯收入的60%确定。
  设区的市农村五保供养标准,由设区的市民政部门会同财政、统计等部门拟定,报本级人民政府批准;县(市、区)农村五保供养标准,由县(市、区)民政部门会同财政、统计等部门拟定,报本级人民政府批准。
  经批准的农村五保供养标准,应当在每年3月底前上报省人民政府备案后公布执行。
  第十一条农村五保供养实行集中供养为主、分散供养为辅的制度。农村五保供养对象可以自行选择供养形式。
  集中供养的农村五保供养对象,由农村五保供养服务机构提供供养服务;因特殊原因不愿或者不宜集中供养的,可以采取院户挂钩的办法,落实其供养服务和管理。
  分散供养的农村五保供养对象,可以由村民委员会或者其委托的村民提供照料,也可以由农村五保供养服务机构提供有关供养服务。
  第十二条乡(镇)人民政府应当与村民委员会或者农村五保供养服务机构签订供养服务协议。供养协议应当载明双方的权利义务、供养的内容和标准。
  第十三条农村五保供养对象将承包土地交由他人代耕的,收益归该农村五保供养对象所有;实行集中供养的,其收益可以委托农村五保供养服务机构管理。
  农村五保供养对象的房屋等私人财产和承包土地的经营、使用、管理及其权益的处置,乡(镇)人民政府或者村民委员会应当与农村五保供养对象依法签订有关协议;农村五保供养对象死亡后,其私人财产及承包的土地按照协议的约定和有关法律、法规的规定处理。

  第三章 农村五保供养服务机构

  第十四条各级人民政府应当加强对农村五保供养服务机构的规划与建设,满足本行政区域农村五保集中供养的需求。
  农村五保供养服务机构的建设选址,应当遵循交通便利,环境安全、卫生,有利于农村五保供养对象生活和身心健康的原则。
  县级人民政府和乡(镇)人民政府应当为其设立的农村五保供养机构提供必要的设备、资金,配备必要的工作人员。
  第十五条农村五保供养服务机构,是公益性的社会福利机构。
  政府举办的或者其他组织利用国有资产举办的农村五保供养服务机构,符合登记条件的,按照国家和省有关事业单位登记管理的规定办理登记。
  对企事业单位、团体和其他社会力量以及公民个人利用非国有资产举办,从事非营利服务的农村五保供养服务机构,符合登记条件的,按照国家和省有关民办非企业单位登记管理的规定办理登记。
  第十六条农村五保供养服务机构实行院长(主任)负责制。院长(主任)应当具有高中以上文化程度,品行良好,身体健康。以事业单位登记的农村五保供养服务机构的院长(主任)由农村五保供养服务机构所在乡(镇)人民政府委派或者聘任,并报县(市、区)民政部门备案。
  农村五保供养服务机构工作人员应当爱岗敬业,身体健康,严格执行相关的规章制度。
  所在乡(镇)人民政府和农村五保供养服务机构应当切实保障农村五保供养服务机构工作人员的合法权益。
  第十七条农村五保供养服务机构应当遵循民主管理、文明办院、敬老养老的原则,建立健全管理制度。
  农村五保供养服务机构应当成立管理委员会。管理委员会成员在农村五保供养服务机构工作人员和全体供养对象中民主选举产生;管理委员会成员中,供养对象所占比例不得少于二分之一。
  管理委员会负责审议农村五保供养服务机构重要事项,协助做好供养工作,检查、监督院长(主任)和工作人员的履职情况。
  第十八条农村五保供养服务机构在保证满足农村五保供养对象的条件下,可以向社会提供自费寄养服务,对要求自费寄养的在乡孤老优抚对象、革命“三老”人员、计划生育独生女儿户老年人等,应当给予优先优惠。
  第十九条农村五保供养服务机构应当维护供养对象的合法权益,不得歧视、侮辱、虐待或者遗弃供养对象,对侵害供养对象人身和财产权利的行为,任何单位和个人均有权制止、举报。
  农村五保供养服务机构应当鼓励供养对象参加有利于其身心健康的活动。
  第二十条农村五保供养服务机构的供养对象应当遵守相关的规章制度,爱护公物,文明礼貌,团结互助,和睦相处,自觉维护正常管理和生活秩序。
  第二十一条任何单位、个人不得侵占、损坏农村五保供养服务机构的土地、房屋、设备和其他财产,或者擅自改变土地、房屋、设备的用途;不得贪污、挪用、截留、私分农村五保供养资金。
  第二十二条农村五保供养服务机构应当遵守有关法律、法规,为供养对象提供符合要求的供养服务,定期公布资金、物资使用和伙食标准、生产经营账目等情况,自觉接受供养对象、有关部门的监督。

  第四章保障与监督管理

  第二十三条设区的市、县(市、区)人民政府应当按照批准的农村五保供养标准在财政预算中安排供养资金。乡(镇)人民政府应当按照上级人民政府核定的供养标准安排供养资金。财政部门应当及时足额拨付农村五保供养资金。
  有农村集体经营等收入的地方,可以从农村集体经营等收入中安排资金,用于补助和改善农村五保供养对象的生活。
  省人民政府每年在财政预算中安排一定的资金,用于全省的农村五保供养工作;对经济欠发达地区和海岛地区的农村五保供养工作给予重点扶持。
  第二十四条农村五保供养服务机构可以组织开展以改善供养对象生活为目的农副业生产。县级以上人民政府及其有关部门应当对农村五保供养服务机构开展农副业生产给予必要的扶持。农村五保供养服务机构的建设用地中,可以留有一定比例的土地开展农副业生产。
  政府主办和特许经营的供水、供电、供气、通信、有线电视等经营单位,应当按照国家和省有关规定为农村五保供养服务机构减免有关费用。
  第二十五条农村五保供养服务机构可以按照国家规定享受税收减免优惠政策。
  社会组织和个人向农村五保供养服务机构提供捐助,符合条件的,可以按照规定在缴纳企业所得税和个人所得税前扣除。
  第二十六条县级以上人民政府有关部门应当有计划地组织开展农村五保供养服务机构工作人员的职业道德、老年医学、服务技能等方面的培训,提高工作人员的整体素质和服务水平。
  第二十七条县级以上人民政府应当依法加强对农村五保供养工作的监督管理。县级以上人民政府民政部门和乡(镇)人民政府应当制定农村五保供养工作的管理制度,并负责督促实施。
  县级以上人民政府财政、审计、民政等有关部门应当加强对农村五保供养资金使用情况的监督管理。
  第二十八条农村五保供养待遇的申请条件、程序、民主评议情况以及农村五保供养的标准和资金使用情况等,应当向社会公告,接受社会监督。

  第五章 法律责任

  第二十九条违反本办法规定的行为,有关法律、法规已有行政处罚、处分规定的,从其规定。
  第三十条农村五保供养服务机构工作人员违反本办法规定,侵犯供养对象的合法权益,歧视、侮辱、虐待或者遗弃供养对象的,由县级以上人民政府民政部门或者乡(镇)人民政府责令限期改正,给予通报批评,对负有责任的主管人员和其他直接责任人员依法给予处分。
  第三十一条违反本办法规定,村民委员会、农村五保供养服务机构对供养对象提供的供养服务不符合要求的,由乡(镇)人民政府责令限期改正;逾期不改正的,乡(镇)人民政府有权终止供养服务协议;造成损失的,依法承担赔偿责任;对负有责任的主管人员和其他直接责任人员依法给予处分。
  第三十二条违反本办法规定的行为,构成犯罪的,依法追究刑事责任。

  第六章 附则

  第三十三条根据需要和条件,当地政府可以采取政府采购的形式,向社会力量举办的养老机构购买农村五保供养服务,但其供养服务水平不得低于当地农村五保供养标准。
  第三十四条本办法自2008年 8月1日起施行。1996年10月25日省人民政府颁布的《浙江省农村五保供养工作实施细则》同时废止。



Provisions for Drug Insert Sheets and Labels

Commissioner of SFDA


Provisions for Drug Insert Sheets and Labels



(SFDA Decree No.24)

The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.


Shao Mingli
Commissioner of SFDA

March 15, 2006





Provisions for Drug Insert Sheets and Labels


Chapter I General Provisions

Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People’s Republic of China and the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China.

Article 2 The insert sheets and labels of drugs marketed within the territory of the People’s Republic of China shall meet the requirements of the Provisions.

Article 3 Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.

A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.

Article 4 A drug label shall be printed on or affixed to the drug package, and no other written words, audio and/or visual materials or other information are attached to introduce or publicize the product or the enterprise.

An insert sheet shall be attached to the smallest package provided by the drug manufacturer for marketing.

Article 5 The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.

Article 6 In the label or insert sheet, the letters or characters shall be clear and easy to be recognized and the marks shall be clear and distinctive. The label and insert sheet shall have no print faded and shall not be affixed unsteadily. Any addition or modification shall not be made by means of pasting, cutting or altering.

Article 7 Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.

Article 8 With the aim to protect public health and direct the rational use of drugs, drug manufacturers may voluntarily apply to add warnings to drug insert sheets or labels. The State Food and Drug Administration may also request drug manufacturers to add warnings to drug insert sheets or labels.


Chapter II Drug Insert Sheet

Article 9 A drug insert sheet shall include the significant scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The specific format, content and writing requirements of drug insert sheet shall be prescribed and issued by the State Food and Drug Administration.

Article 10 Disease names, pharmaceutical terms, drug names, the names and results of clinical testing in drug insert sheets shall be expressed in professional terms published or standardized by the State. The units of measurement shall conform to the national standards.

Article 11 All the active ingredients or medicinal ingredients of traditional Chinese medicines in a prescription shall be listed in the insert sheet. For injections and non-prescription drugs, all excipients shall be listed as well.

The ingredients or excipients included in a prescription, which may cause severe adverse reaction, shall be specified.

Article 12 A drug manufacturer shall trace the safety and efficacy of its marketed drugs. For any modification to the insert sheet, an application shall be submitted timely.

The State Food and Drug Administration may also require a drug manufacturer to make modification to the insert sheet on the basis of the results of adverse drug reaction monitoring and drug re-evaluation.

Article 13 After the modification to the insert sheet is approved, the drug manufacturer shall inform relevant drug distributors, drug users and other departments of the modified content immediately, and use the modified insert sheet and label timely as required.

Article 14 The insert sheet shall provide full information on adverse drug reaction and indicate the adverse reactions in detail. A drug manufacturer, who fails to timely modify the insert sheet on the basis of the safety and efficacy data of the marketed drug or to fully explain the adverse reaction in the insert sheet, shall be liable for all the consequences arising therefrom.

Article 15 The approval date and the modification date shall be distinctively shown in the insert sheet.


Chapter III Drug Labels

Article 16 Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.

Article 17 The inner label shall bear such drug information as the adopted name in China, indications or functions, strength, dose and usage, production date, batch number, expiry date and manufacturer. If there is no enough space in the package to include all the information mentioned above, the adopted name in China, strength, batch number and expiry date shall be indicated at least.

Article 18 The outer label of a drug shall indicate such information as the adopted name in China, ingredients, description, indications or functions, strength, dose and usage, adverse reactions, contraindications, precautions, storage, production date, batch number, expiry date, approval number and manufacturer. Where indications or functions, dose and usage, adverse reactions, contraindications and precautions cannot be fully noted, main information plus a “See drug insert sheet for details.” notice shall be indicated.

Article 19 The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.

Article 20 The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated.

Article 21 Where one drug produced by a manufacturer has the same drug strength and packaging specification, the content, format and color of its labels must be the same. Where one drug produced by a manufacturer has different drug strengths or packaging specifications, its labels shall be clearly distinguished from one another, or its specifications shall be notably marked in the corresponding specification items.

Where a drug produced by a manufacturer is administrated as prescription drug and non-prescription drug respectively, their packaging colors shall be distinctly different.

Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.

Article 23 The expiry date in the drug label shall appear in the order of year, month and day, with year shown in four digits, month and day in two digits. Its specific format shall be “Valid till XXXX year XX month” or “Valid till XXXX year XX month XX day”. It may be presented with numbers and other symbols as “Valid till XXXX.XX.” or “Valid till XXXX/XX/XX”.

For the preventive biological product, the expiry date shall be labeled according to the registration specifications approved by the State Food and Drug Administration. The expiry date of the biological product for therapeutic use shall be counted from the filling date. For other drugs, the expiry date shall be counted from the production date.

Where the expiry date is labeled to the day, it shall be marked as one day earlier than the actual expiry date; where the expiry date is labeled to the month, it shall be marked as one month earlier than the actual expiry month.


Chapter IV Use of Drug Name and Registered Trademark

Article 24 The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.

Article 25 The adopted name in China shall be conspicuous and prominent, and its typeface, size and color shall be consistent, and meet the following requirements:
(1) For horizontal labels, the adopted name in China shall appear in a prominent position within the area of the upper one-third of the label; for vertical labels, it shall appear in a prominent position within the area of the right one-third of the label;
(2) No such illegible typefaces as cursive characters and seal characters shall be used, and no such format as italics, margining and shading shall be used to modify the typefaces.
(3) The font color of the adopted name in China shall be black or white, in sharp contrast to the light-colored or dark-colored background respectively.
(4) Writing in separate lines shall be avoided unless limited by the packaging size.

Article 26 The trade name of a drug shall not be placed in the same line with the adopted name in China; its typeface and color shall be no more conspicuous than that of the adopted name in China, and its font area per character shall be no bigger than half of that of the adopted name in China.

Article 27 Unregistered trademarks and other drug names unapproved by the State Food and Drug Administration shall not be used in the drug insert sheets and labels.

Where a registered trademark is used in a drug label, it shall be printed in a corner of the label. Where a registered trademark contains characters, the font area per character shall be no bigger than a quarter of that of the adopted name in China.


Chapter V Other Provisions

Article 28 For narcotic drugs, psychotropic substances, medicinal toxic drugs, radioactive pharmaceuticals, drugs for topical use, non-prescription drugs and other drugs having special marks specified by the State, their special marks shall be printed in the drug insert sheets and labels.
Where there are special provisions issued by the State for drug insert sheets and labels, they shall prevail.

Article 29 The labeling provisions for Chinese crude drugs and prepared slices of Chinese crude drugs shall be formulated separately by the State Food and Drug Administration.

Article 30 Where drug insert sheets and labels are not in compliance with the Provisions, a punishment shall be imposed in accordance with the relevant provisions of the Drug Administration Law of the People’s Republic of China.


Chapter VI Supplementary Provisions

Article 31 These Provisions shall come into force as of June 1, 2006. the Provisions for Drug Packaging, Labels and Insert Sheets (Provisional) issued by State Food and Drug Administration on October 15, 2005 shall be annulled therefrom.


财政部 国家计委关于收取林业保护建设费的通知

财政部 国家发展和改革委员会


财政部国家计委关于收取林业保护建设费的通知
 (1994年1月24日 财综字[1994]第7号)


林业部,各省、自治区、直辖市财政厅(局)、物价局(委员会):
  根据《中共中央办公厅、国务院办公厅关于涉及农民负担项目审核处理意见的通知》(中办发[1993]10号)的精神,对涉及农民负担的由林业部门收取的林政管理费和林区管理建设费等收费项目,决定予以取消。为保证林业部门正常的林政管理和林区建设不受影响,经清理农民负担审核小组研究决定,同意设置“林业保护建设费”收费项目。现将有关规定通知如下:


  一、林业保护建设费的收费对象为:除农村集体和林农以外的其他木材销售者(单位和个人)及经林业部门批准可以直接进入林区收购木材的单位。


  二、林业保护建设费由林业部门负责收取,集中用于林政管理、森林防火和对林区中幼林抚育的道路建设,实行专款专用,具体使用管理办法由各省、自治区、直辖市财政部门会同林业部门制定。


  三、林业保护建设费的收取范围仅限于南方集体林区,其他省区对本省区内的地方国营林场生产销售的木材可参照执行。林业保护建设费的收费标准及其他省区参照执行的具体标准,由国家计委会同财政部核定后另行发布。


  四、各地林业部门收取的林业保护建设费,作为预算外资金管理,执行预算外资金管理的有关规定,实行财政专户储存,做到收支两条线,并严格按照规定的开支范围使用,不得挪作他用。